Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral CR845 in Patients With PBC and Moderate-to-Severe Pruritus
NCT03995212Phase 2Terminated
- Sponsor
- Cara Therapeutics, Inc.
- Start
- Jun 2019
- Primary completion
- Jun 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of difelikefalin in cholestatic pruritus, sponsored by Cara Therapeutics, Inc.. Started Jun 2019; status: terminated.
02
Drugs
difelikefalin
03
Conditions
cholestatic pruritus
Beyond the preview
Go deeper on NCT03995212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03995212.